Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging misleading statements and failure to disclose critical information that may have impacted shareholders' investments [1]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion and selling of illegitimate versions of Wegovy, risking patient safety, and potential termination of collaboration with Novo Nordisk [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot Corporation is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition, raising doubts about its ability to operate profitably as a standalone company [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene Corporation is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include lower-than-expected enrollment and increased market morbidity affecting over two-thirds of Centene's marketplace share, leading to misleading statements about the company's prospects [4]. Group 4: Biohaven Ltd. (NYSE: BHVN) - The class period for Biohaven Ltd. is from March 24, 2023, to May 14, 2025, with a lead plaintiff deadline of September 12, 2025 [5]. - Allegations involve overstated regulatory prospects for treatments and potential negative impacts on Biohaven's business and financial condition once the truth is revealed [5].

Core Points - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. for alleged securities fraud occurring between April 29, 2025, and June 23, 2025 [1][2] - The lawsuit claims that Hims was involved in deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2] - Investors affected by the alleged fraud have until August 25, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs for class members to participate [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157789&from=3 CLASS PERIOD: A ...

NEW YORK, July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157769&from=4CLASS PERIOD: April 29, ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains semaglutide, but allegedly misrepresented the nature of this partnership [3][4]. Group 3: Impact on Stock Price - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share within three days [5].

Group 1 - A securities fraud investigation has been initiated into Hims & Hers Health Inc. regarding potential violations of the Securities Exchange Act of 1934, focusing on misleading information about regulatory compliance and business operations [1] - Following the termination of a collaboration with Novo Nordisk on June 23, 2025, Hims & Hers' stock experienced a decline of over 34% [2] - A class action lawsuit has been filed against Hims & Hers, alleging the company failed to disclose risks associated with its compounded drug offerings during the Class Period from April 29, 2025, to June 22, 2025 [2]

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and prospects were allegedly materially misleading and lacked a reasonable basis [2]. Lead Plaintiff Process - Investors in Hims & Hers have until August 25, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class in the litigation [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

RADNOR, Pa., July 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25 ...

Core Insights - Hims & Hers Health, Inc. has made significant progress in international expansion, highlighted by the acquisition of ZAVA, a European digital health platform, which provides access to over 1.3 million active customers and nearly 2.3 million consultations in 2024 [1][7] - The company plans to enter the Canadian market, offering a low-cost weight loss program coinciding with the global launch of generic semaglutide, targeting the obesity treatment market [2][7] - Hims & Hers is transitioning from a U.S.-centric platform to a global digital health leader through strategic acquisitions and localized care delivery [3][7] Financial Performance - Hims & Hers shares have increased by 96.8% year to date, outperforming the industry growth of 6.2% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 177.8% improvement from 2024 [8] Valuation Metrics - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 4.1X, which is lower than the industry's average of 5.5X but higher than its three-year median of 2.3X [10] - The company currently holds a Zacks Rank 1 (Strong Buy) [12]